Completion of Phase 2a clinical study for the treatment of fibromyalgia at the University of Michigan -Total of five patients dosed with TRP-8802 (oral psilocybin) and administered psychotherapy to explore the use for the treatment of patients with fibromyalgia More: https://lnkd.in/g2d8uPK4 #TYP #psychedelic #health #ASX #ASXnews
Tryp Therapeutics
Biotechnology Research
San Diego, California 2,334 followers
Tryp is leading the next wave of psychedelic drug development.
About us
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has an ongoing Phase 2a clinical trial for the treatment of Binge Eating Disorder at the University of Florida and an upcoming Phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit has been demonstrated, subsequent studies are expected to utilize TRP-8803 which has the potential to further improve efficacy, safety and patient experience.
- Website
-
http://tryptherapeutics.com
External link for Tryp Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Diego, California
- Type
- Public Company
Locations
-
Primary
8910 University Center Ln
San Diego, California 92122, US
Employees at Tryp Therapeutics
Updates
-
Tryptamine Therapeutics (ASX: TYP) CEO Jason Carroll will be presenting at the Bioshares Biotech Summit 2024, held at the Esplanade Hotel in Fremantle at 10:35 am on July 13, 2024. To register: https://lnkd.in/guGtZq_R #TYP #psychedelic #health #ASX #ASXnews
-
-
🛎️Via Investor Stream #SmallCapCentral: Tryp Therapeutics (ASX: TYP) completes its Phase 2a clinical trial for the treatment of fibromyalgia https://lnkd.in/g68xKcCH #TrypTherapeutics #TYP #psychedelic #fibromyalgia #health #ASX #ASXnews Alex Paull
-
Tryp Therapeutics reposted this
📢#ASXNews: Tryp Therapeutics (ASX: TYP) Completion of Phase 2a clinical study for the treatment of fibromyalgia at the University of Michigan -Total of five patients dosed with TRP-8802 (oral psilocybin) and administered #psychotherapy to explore the use for the treatment of patients with #fibromyalgia, a condition associated with widespread pain More: https://lnkd.in/g2d8uPK4 Stay updated: https://lnkd.in/gwBTkjRA #InvestorStream #TrypTherapeutics #TYP #psychedelic #health #ASX #investing #news
-
-
📰JustStocks: Tryptamine Therapeutics Ltd (ASX:TYP) has completed the Phase 2a clinical study of TRP-8802 for treating fibromyalgia at the University of Michigan. #TYP #psychedelic #health #ASX #ASXnews https://lnkd.in/gVn9zibD
-
ICYMI: Completion of Phase 2a clinical study for the treatment of fibromyalgia at the University of Michigan. Read 👇 #TYP #psychedelic #health #ASX #ASXnews
-
Tryp Therapeutics (ASX: TYP) CEO Jason Carroll will be presenting at an investor lunch in Fremantle on Friday, July 12, 2024. See details below. Hope to see you there! RSVP: 📞 0407 429 027 (Non-Executive Director, Chris Ntoumenopoulos) #TYP #ASX #psychedelic #investing #news
-
-
Via 🛎️Investor Stream #SmallCapCentral: Tryp Therapeutics (ASX: TYP) successfully completes maiden dosing of IV-infused psilocin in a world-first Watch on YouTube: https://lnkd.in/g3P-5Sgv #TYP #psychedelic #health #ASX #ASXnews Jason Carroll Alex Paull
-
📰Small Caps: Recently-listed biotech company Tryptamine Therapeutics (ASX: TYP) has successfully completed the world’s first dosing of a patient with intravenous (IV)-infused psilocin (TRP-8803) in South Australia. #TYP #psychedelic #ASX #ASXnews https://lnkd.in/g5nHiCBP
Tryptamine Therapeutics achieves milestone of world's first IV-infused psilocin dosing
smallcaps.com.au
-
📰Grafa: Tryptamine Therapeutics completed the first-ever dosing of its proprietary TRP-8803 (IV-infused psilocin) in a human participant. The trial represents a milestone in the use of psychedelic treatments. #TYP #psychedelic #ASX #ASXnews https://lnkd.in/gSEpBDNu
Tryptamine Therapeutics (ASX:TYP) completes first-ever dosing of psilocin in human trial
grafa.com